Targeted Intracellular Degradation of SARS-CoV-2 via Computationally-Optimized Peptide Fusions
Lists
Only you see this
Abstract
The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has elicited a global health crisis of catastrophic proportions. With only a few vaccines approved for early or limited use, there is a critical need for effective antiviral strategies. In this study, we report a unique antiviral platform, through computational design of ACE2-derived peptides which both target the viral spike protein receptor binding domain (RBD) and recruit E3 ubiquitin ligases for subsequent intracellular degradation of SARS-CoV-2 in the proteasome. Our engineered peptide fusions demonstrate robust RBD degradation capabilities in human cells and are capable of inhibiting infection-competent viral production, thus prompting their further experimental characterization and therapeutic development.
BibTeX
@inproceedings{chatterjee2020targeted,
author = {Pranam Chatterjee and Manvitha Ponnapati and Christian Kramme and Alexandru M. Pleşa and George M. Church and Joseph M. Jacobson},
title = {{Targeted Intracellular Degradation of SARS-CoV-2 via Computationally-Optimized Peptide Fusions}},
booktitle = {Zenodo},
year = {2020},
doi = {10.5281/zenodo.4151380},
}Loading related content...